Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/07/23 | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
 |
42 | |
| 03/17/23 | Annual report pursuant to Section 13 and 15(d) |
|
|
179 | |
| 03/15/23 | Current report filing |
|
|
8 | |
| 02/23/23 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 02/23/23 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 02/16/23 | Current report filing |
|
|
6 | |
| 02/15/23 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 02/15/23 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 01/31/23 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
12 | ||
| 01/06/23 | Statement of changes in beneficial ownership of securities |
|
1 |